The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

didanosine     9-[(2R,5S)-5- (hydroxymethyl)oxolan-2- yl]...

Synonyms: Didanosina, Didanosinum, Videx, ddIno, DIDEOXYINOSINE, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of didanosine


Psychiatry related information on didanosine


High impact information on didanosine


Chemical compound and disease context of didanosine


Biological context of didanosine


Anatomical context of didanosine

  • Bone marrow toxicity of dideoxyinosine [23].
  • In patients treated with zidovudine plus didanosine at months 1, 3 and 6, the mean decrease in plasma HIV-1 RNA was 1.40, 1.25 and 1.12 log10 and in semen 1.10, 1.41 and 1.32 log10, respectively [24].
  • HIV-infected DRG cultures exposed to indinavir or didanosine showed significant neuronal atrophy, neurite retraction, and process loss, compared with controls [25].
  • METHODS: Predictors of achieving and maintaining pVL suppression were examined in a randomized trial of combinations of zidovudine, nevirapine and didanosine in patients with CD4+ T cell counts of between 200 and 600 x 10(6) cells/l who were naive to antiretroviral therapy and AIDS-free at enrolment [26].
  • CONCLUSIONS: This data supports the strategy that in cases of symptomatic hyperlactatemia or lactic acidosis in which the toxicity is associated with stavudine, didanosine or both, it is safe and efficacious to reintroduce NRTI that are less potent inhibitors of mitochondria [27].

Associations of didanosine with other chemical compounds


Gene context of didanosine


Analytical, diagnostic and therapeutic context of didanosine


  1. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. Kahn, J.O., Lagakos, S.W., Richman, D.D., Cross, A., Pettinelli, C., Liou, S.H., Brown, M., Volberding, P.A., Crumpacker, C.S., Beall, G. N. Engl. J. Med. (1992) [Pubmed]
  2. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. Englund, J.A., Baker, C.J., Raskino, C., McKinney, R.E., Petrie, B., Fowler, M.G., Pearson, D., Gershon, A., McSherry, G.D., Abrams, E.J., Schliozberg, J., Sullivan, J.L. N. Engl. J. Med. (1997) [Pubmed]
  3. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. Saravolatz, L.D., Winslow, D.L., Collins, G., Hodges, J.S., Pettinelli, C., Stein, D.S., Markowitz, N., Reves, R., Loveless, M.O., Crane, L., Thompson, M., Abrams, D. N. Engl. J. Med. (1996) [Pubmed]
  4. AIDS dementia complex and didanosine. Portegies, P., Enting, R.H., de Jong, M.D., Danner, S.A., Reiss, P., Goudsmit, J., Lange, J.M. Lancet (1994) [Pubmed]
  5. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. Conway, B., Wainberg, M.A., Hall, D., Harris, M., Reiss, P., Cooper, D., Vella, S., Curry, R., Robinson, P., Lange, J.M., Montaner, J.S. AIDS (2001) [Pubmed]
  6. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. Ribera, E., Azuaje, C., Lopez, R.M., Domingo, P., Curran, A., Feijoo, M., Pou, L., Sánchez, P., Sambeat, M.A., Colomer, J., Lopez-Colomes, J.L., Crespo, M., Falcó, V., Ocaña, I., Pahissa, A. J. Antimicrob. Chemother. (2007) [Pubmed]
  7. Pilot Study of Didanosine in Patients with HIV Dementia. Kieburtz, K.D., Price, R.W., Sidtis, J.J., Hall, C., Grundman, M., McLaren, C. Journal of neuro-AIDS. (1996) [Pubmed]
  8. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. Luzuriaga, K., Bryson, Y., Krogstad, P., Robinson, J., Stechenberg, B., Lamson, M., Cort, S., Sullivan, J.L. N. Engl. J. Med. (1997) [Pubmed]
  9. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. Gao, W.Y., Shirasaka, T., Johns, D.G., Broder, S., Mitsuya, H. J. Clin. Invest. (1993) [Pubmed]
  10. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lisziewicz, J., Jessen, H., Finzi, D., Siliciano, R.F., Lori, F. Lancet (1998) [Pubmed]
  11. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Brun-Vézinet, F., Boucher, C., Loveday, C., Descamps, D., Fauveau, V., Izopet, J., Jeffries, D., Kaye, S., Krzyanowski, C., Nunn, A., Schuurman, R., Seigneurin, J.M., Tamalet, C., Tedder, R., Weber, J., Weverling, G.J. Lancet (1997) [Pubmed]
  12. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Malley, S.D., Grange, J.M., Hamedi-Sangsari, F., Vila, J.R. Lancet (1994) [Pubmed]
  13. Clinical response to dideoxyinosine in patients with HIV infection resistant to zidovudine. Bach, M.C. N. Engl. J. Med. (1990) [Pubmed]
  14. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Sahai, J., Garber, G., Gallicano, K., Oliveras, L., Cameron, D.W. Ann. Intern. Med. (1995) [Pubmed]
  15. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Raffi, F., Reliquet, V., Ferré, V., Arvieux, C., Hascoet, C., Bellein, V., Besnier, J.M., Breux, J.P., Garré, M., May, T., Molina, J.M., Perré, P., Raguin, G., Rozenbaum, W., Zucman, D. Antivir. Ther. (Lond.) (2000) [Pubmed]
  16. Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase. Salomon, H., Montaner, J.S., Belmonte, A., Wainberg, M.A. Antivir. Ther. (Lond.) (1998) [Pubmed]
  17. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Moreno, A., Quereda, C., Moreno, L., Perez-Elías, M.J., Muriel, A., Casado, J.L., Antela, A., Dronda, F., Navas, E., Bárcena, R., Moreno, S. Antivir. Ther. (Lond.) (2004) [Pubmed]
  18. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. Montaner, J.S., Schechter, M.T., Rachlis, A., Gill, J., Beaulieu, R., Tsoukas, C., Raboud, J., Cameron, B., Salomon, H., Dunkle, L., Smaldone, L., Wainberg, M.A. Ann. Intern. Med. (1995) [Pubmed]
  19. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Cohen, O.J., Pantaleo, G., Holodniy, M., Schnittman, S., Niu, M., Graziosi, C., Pavlakis, G.N., Lalezari, J., Bartlett, J.A., Steigbigel, R.T. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  20. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients. Reliquet, V., Ferré, V., Hascoet, C., Besnier, J.M., Bellein, V., Arvieux, C., Molina, J.M., Breux, J.P., Zucman, D., Rozenbaum, W., Allavena, C., Raffi, F. Antivir. Ther. (Lond.) (1999) [Pubmed]
  21. Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. Rodríguez de la Concepción, M.L., Yubero, P., Domingo, J.C., Iglesias, R., Domingo, P., Villarroya, F., Giralt, M. Antivir. Ther. (Lond.) (2005) [Pubmed]
  22. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Schacter, L.P., Rozencweig, M., Beltangady, M., Allan, J.D., Canetta, R., Cooley, T.P., Dolin, R., Kelley, S., Lambert, J., Liebman, H.A. Blood (1992) [Pubmed]
  23. Bone marrow toxicity of dideoxyinosine. Molina, J.M., Groopman, J.E. N. Engl. J. Med. (1989) [Pubmed]
  24. A combination of nucleoside analogues and a protease inhibitor reduces HIV-1 RNA levels in semen: implications for sexual transmission of HIV infection. Liuzzi, G., Chirianni, A., Bagnarelli, P., Clementi, M., Piazza, M. Antivir. Ther. (Lond.) (1999) [Pubmed]
  25. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor-mediated neurotoxicity. Pettersen, J.A., Jones, G., Worthington, C., Krentz, H.B., Keppler, O.T., Hoke, A., Gill, M.J., Power, C. Ann. Neurol. (2006) [Pubmed]
  26. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. Raboud, J.M., Montaner, J.S., Conway, B., Rae, S., Reiss, P., Vella, S., Cooper, D., Lange, J., Harris, M., Wainberg, M.A., Robinson, P., Myers, M., Hall, D. AIDS (1998) [Pubmed]
  27. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. Lonergan, J.T., Barber, R.E., Mathews, W.C. AIDS (2003) [Pubmed]
  28. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea. Zala, C., Salomón, H., Cahn, P. Antivir. Ther. (Lond.) (1999) [Pubmed]
  29. Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine. Rusconi, S., La Seta Catamancio, S., Citterio, P., Bulgheroni, E., Kurtagic, S., Galazzi, M., Croce, F., Moroni, M., Galli, M. Antivir. Ther. (Lond.) (2001) [Pubmed]
  30. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Piccinini, M., Rinaudo, M.T., Anselmino, A., Buccinnà, B., Ramondetti, C., Dematteis, A., Ricotti, E., Palmisano, L., Mostert, M., Tovo, P.A. Antivir. Ther. (Lond.) (2005) [Pubmed]
  31. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. Karlsson, I., Antonsson, L., Shi, Y., Karlsson, A., Albert, J., Leitner, T., Olde, B., Owman, C., Fenyö, E.M. AIDS (2003) [Pubmed]
  32. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Murakami, J., Nagai, N., Shigemasa, K., Ohama, K. Eur. J. Cancer (1999) [Pubmed]
  33. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine. Von Tungeln, L.S., Dobrovolsky, V.N., Bishop, M.E., Shaddock, J.G., Heflich, R.H., Beland, F.A. Mutagenesis (2004) [Pubmed]
  34. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. Abrams, D.I., Goldman, A.I., Launer, C., Korvick, J.A., Neaton, J.D., Crane, L.R., Grodesky, M., Wakefield, S., Muth, K., Kornegay, S. N. Engl. J. Med. (1994) [Pubmed]
  35. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Montaner, J.S., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M.A., Smith, D., Robinson, P., Hall, D., Myers, M., Lange, J.M. JAMA (1998) [Pubmed]
  36. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Paton, N.I., Aboulhab, J., Karim, F. Lancet (2002) [Pubmed]
  37. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Sproat, M., Pozniak, A.L., Peeters, M., Winters, B., Hoetelmans, R., Graham, N.M., Gazzard, B.G. Antivir. Ther. (Lond.) (2005) [Pubmed]
  38. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. King, J.R., Nachman, S., Yogev, R., Hodge, J., Aldrovandi, G., Damle, B., Smith, E., Wiznia, A., Acosta, E.P. Antivir. Ther. (Lond.) (2002) [Pubmed]
WikiGenes - Universities